| Original language | English (US) |
|---|---|
| Pages (from-to) | 867-870 |
| Number of pages | 4 |
| Journal | Pharmacogenomics |
| Volume | 20 |
| Issue number | 12 |
| DOIs | |
| State | Published - Aug 27 2019 |
Bibliographical note
Funding Information:JR Strawn has received research support from the National Institutes of Health (NIMH/NIEHS) as well as Allergan and Neuronetics. He has received material support from Myriad Genetics and receives royalties from the publication of two texts (Springer). He serves as an author for UpToDate, an Associate Editor for Current Psychiatry and has received honoraria from CMEology. LB Ramsey has received research support from the National Institutes of Health (NICHD) and BTG, International Ltd. JR Bishop receives grant support from NIH (NCCIH). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Keywords
- CYP2C19
- CYP2D6
- SSRIs
- antidepressants
- pharmacogenetics
- psychiatry